###begin article-title 0
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
The CD44+/CD24- phenotype is enriched in basal-like breast tumors
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 120 122 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast tumors are heterogeneous and consist of phenotypically diverse cells. Breast cancer cells with a CD44+/CD24- phenotype have been suggested to have tumor-initiating properties with stem cell-like and invasive features, although it is unclear whether their presence within a tumor has clinical implications. There is also a large heterogeneity between tumors, illustrated by reproducible stratification into various subtypes based on gene expression profiles or histopathological features. We have explored the prevalence of cells with different CD44/CD24 phenotypes within breast cancer subtypes.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 90 95 <span type="species:ncbi:9606">human</span>
Double-staining immunohistochemistry was used to quantify CD44 and CD24 expression in 240 human breast tumors for which information on other tumor markers and clinical characteristics was available. Gene expression data were also accessible for a cohort of the material.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 238 240 238 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 254 256 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 278 280 278 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 407 409 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 712 713 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 718 720 718 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 735 736 735 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 741 743 741 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 824 826 824 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 840 841 840 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 846 848 846 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 918 919 914 915 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
A considerable heterogeneity in CD44 and CD24 expression was seen both between and within tumors. A complete lack of both proteins was evident in 35% of the tumors, while 13% contained cells of more than one of the CD44+/CD24-, CD44-/CD24+ and CD44+/CD24+ phenotypes. CD44+/CD24- cells were detected in 31% of the tumors, ranging in proportion from only a few to close to 100% of tumor cells. The CD44+/CD24- phenotype was most common in the basal-like subgroup - characterized as negative for the estrogen and progesterone receptors as well as for HER2, and as positive for cytokeratin 5/14 and/or epidermal growth factor receptor, and particularly common in BRCA1 hereditary tumors, of which 94% contained CD44+/CD24- cells. The CD44+/CD24- phenotype was surprisingly scarce in HER2+ tumors, which had a predominantly CD24+ status. A CD44+/CD24- gene expression signature was generated, which included CD44 and alpha6-integrin (CD49f) among the top-ranked overexpressed genes.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 121 122 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 127 129 127 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 216 218 216 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
We demonstrate an association between basal-like and particularly BRCA1 hereditary breast cancer and the presence of CD44+/CD24- cells. Not all basal-like tumors and very few HER2+ tumors, however, contain CD44+/CD24- cells, emphasizing that a putative tumorigenic ability may not be confined to cells of this phenotype and that other breast cancer stem cell markers remain to be identified.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer is a truly complex disease with a large inter-tumoral and intra-tumoral heterogeneity resulting in highly variable clinical behavior and response to therapy. The maintenance of the heterogeneity of cells within a tumor is not fully understood. Possibly, every cell within a tumor may have a capacity to proliferate and form new tumors, although the likelihood for each cell is very low. Alternatively, only a small subset of cells with distinct characteristics has the capacity to maintain tumor growth.
###end p 11
###begin p 12
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 26 32 26 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 381 382 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 387 393 387 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 546 547 546 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 552 554 552 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
A population of CD44+/CD24-/low cells has been demonstrated to have tumor-initiating properties in breast cancer [1]. This tumorigenic phenotype has been associated with stem cell-like characteristics [2], with enhanced invasive properties [3], with radiation resistance [4] and with distinct genetic profiles suggesting correlation to adverse prognosis [5]. The prevalence of CD44+/CD24-/low cells within breast tumors, however, has not been significantly associated with clinical characteristics - although tumors with a higher fraction of CD44+/CD24- cells were more commonly found in patients diagnosed with distant metastases [6].
###end p 12
###begin p 13
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 534 535 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 942 944 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 945 947 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Breast cancers have been classified based on their gene expression profiles into luminal A and B, basal-like, HER2+ and normal breast-like subtypes [7-10]. These subtypes have been associated with diverse tumor characteristics and clinical outcome. The luminal subtypes are associated with expression of the estrogen receptor (ER), while basal-like and normal-like tumors are essentially all ER-negative, as are the majority of HER2+ tumors. Multiple studies have demonstrated basal-like tumors to have a particularly poor prognosis [8,9,11], although it is unclear whether basal-like tumors have a significantly worse clinical outcome than other ER-negative tumors [12]. Immunohistochemical features have been used to characterize basal-like tumors as typically negative for ER, for the progesterone receptor (PgR) and for HER2 but positive for basal cytokeratins (CK5/6/14/17), for epidermal growth factor receptor (EGFR) and/or for c-kit [13-15].
###end p 13
###begin p 14
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 31 37 31 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 312 313 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 318 320 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 505 506 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 511 513 511 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 111 116 <span type="species:ncbi:9606">human</span>
###xml 209 214 <span type="species:ncbi:9606">human</span>
A correlation of the CD44+/CD24-/low phenotype to specific breast cancer subtypes has not yet been reported in human breast tumors. In the present article we have determined the expression of CD44 and CD24 in human breast tumors using double-staining immunohistochemistry and have correlated the presence of CD44+/CD24- cells to subgroups of breast cancer, classified using the expression of ER, PgR, HER2, CK5/14 and EGFR, as well as by mRNA expression profiles. We demonstrate an association of the CD44+/CD24- phenotype to basal-like and BRCA1 hereditary breast cancer.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 16
###begin p 17
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
We studied 240 tumors from a cohort of 445 patients surgically treated for stage II breast cancer (age 31 to 81 years), diagnosed in the South Swedish Health Care Region between 1985 and 1994 and originally participating in two randomized clinical trials [16,17]. All patients received 2 years of adjuvant tamoxifen treatment, without stratification according to ER status. The median follow-up time for patients alive and free from metastasis at the last follow-up visit was 5.3 years. The current study was approved by the Lund University Medical Ethics Committee.
###end p 17
###begin title 18
Tumor characteristics
###end title 18
###begin p 19
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Fresh-frozen tumor tissue was used for routine determination of cytosolic ER and PgR, as well as the S-phase fraction, using an enzyme immunoassay and DNA flow cytometry, respectively, as described earlier [18,19]. Cores of 0.6 mm diameter formalin-fixed, paraffin-embedded tumor tissue were used to generate tissue microarrays (TMAs) for the 445 cases. Three cores from every individual tumor were arrayed. These TMAs have been used for immunohistochemical staining of CK5, CK14, EGFR and cytokeratin clone AE1/AE3 as described previously [12,20]. A pathologist re-evaluated the histological type on whole formalin-fixed paraffin-embedded sections [21].
###end p 19
###begin title 20
BRCA1 tissue microarray
###end title 20
###begin p 21
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
An additional TMA consisting of tumors from 23 BRCA1 germline mutation carriers, diagnosed in Sweden between 1980 and 2001, was used for evaluation purpose. This TMA was generated as described above, including two or three cores from each tumor.
###end p 21
###begin title 22
Immunohistochemical staining
###end title 22
###begin p 23
Sections (4 mum) of the TMA blocks were mounted on Dako REALtrade mark Capillary Gap Microscope Slides (DAKO, Glostrup, Denmark), were deparaffinized in xylene and were rehydrated in ethanol. Antigen retrieval was achieved either by placing slides in Tris-ethylenediamine tetraacetic acid buffer (pH 9.0) at 125degreesC in a 2100 Retriever (PickCell Laboratories, Amsterdam, the Netherlands) for 5 minutes (CD44/CD24), or by microwaving the slides in Tris-ethylenediamine tetraacetic acid buffer (pH 9.0) for 7 minutes at 800 W followed by 15 minutes at 350 W (HER2).
###end p 23
###begin p 24
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 146 152 <span type="species:ncbi:9986">Rabbit</span>
###xml 153 158 <span type="species:ncbi:10090">Mouse</span>
Double-immunostaining with antibodies for detection of CD44 and CD24 was performed by an Autostainer (DAKO) using EnVision G|2 Doublestain System Rabbit/Mouse (DAB+/Permanent Red) (DAKO) according to the manufacturer's instructions. Antibodies for the detection of CD44 (Clone 156-3C11, 1:800) and CD24 (Clone SN3b, 1:400) were purchased from Neomarkers (Fremont, CA, USA). CD44 was detected with Permanent Red and CD24 was detected using diaminobenzidene (DAB).
###end p 24
###begin p 25
###xml 25 31 <span type="species:ncbi:9986">rabbit</span>
HER2 was detected with a rabbit polyclonal primary antibody (A0485, 1:1,000; DAKO) followed by EnVisiontrade mark on a TechMatetrade mark (DAKO). All slides were counterstained with hematoxylin for the identification of nuclei.
###end p 25
###begin title 26
Immunohistochemical evaluation
###end title 26
###begin p 27
###xml 39 45 <span type="species:ncbi:9606">person</span>
###xml 190 197 <span type="species:ncbi:9606">patient</span>
The scoring was performed twice by one person in a blinded fashion. All unclear cases were discussed with a pathologist. In case of discrepant staining between the three cores from the same patient, an average was used.
###end p 27
###begin p 28
HER2 scoring was carried out according to the standard procedure (DAKO): 0, < 10% of the tumor cells showed membranous staining; 1, > 10% of the tumor cells were positive but not circumferential; 2, weak staining around the whole membrane in > 10% of the tumor cells; and 3, strong staining around the membrane in > 10% of the tumor cells. CD44 staining was detected mainly in the membrane and the scoring was as follows: 0, 0% positive tumor cells; 1, 1% to 10% positive cells; 2, 11% to 50% positive cells; 3, 51% to 75% positive cells; and 4, 76% to 100% positive cells. CD24 staining was detected mainly in the cytoplasm and the scoring was performed as described for CD44.
###end p 28
###begin p 29
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 28 30 28 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 205 207 205 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The proportion of CD44+/CD24- tumor cells was determined as the percentage of cells positive for Permanent Red staining but negative for DAB staining. The frequencies of CD44-/CD24+ cells and of CD44+/CD24+ cells were determined in a similar fashion.
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 400 402 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Associations between the presence of CD44, CD24 or different CD44/CD24 phenotypes and clinical variables as well as breast cancer subgroups were assessed by Fisher's exact test, except for age where the Mann-Whitney U test was used. The Kaplan-Meier method was used to estimate distant disease-free survival, and the log-rank test to compare survival between two strata. All tests were two-sided and P < 0.05 was considered significant. Statistical analyses were carried out using Stata 10.0 software (Stata Corporation, College Station, TX, USA).
###end p 31
###begin title 32
Microarrays and data analysis
###end title 32
###begin p 33
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
For 168 of the 445 tumors in our cohort, mRNA expression analysis has previously been performed using cDNA microarrays with 27,648 reporters [22,23]. The microarray data for these 168 tumors are available through the Gene Expression Omnibus database (accession numbers GSE6577 and GSE5325). Data pre-processing and filtering for the selected 168 tumors were performed using the BioArray Software Environment [24] as previously described [23], leaving 15,040 reporters that were used for all subsequent analyses.
###end p 33
###begin p 34
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 595 596 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Three independent sets of gene signatures were used to further characterize the tumors. Genes were matched across datasets based on gene symbols, and matched genes were centralized in our dataset across the 168 tumors. Nearest centroid classifiers were used for the Sorlie and colleagues' [9] and the Hu and colleagues' [10] subtype classifications, with each tumor classified based on to which centroid it was most correlated using Pearson correlation. The average expression level for the genes in a signature was used to characterize tumors for the Shipitsin and colleagues' gene signatures [5].
###end p 34
###begin p 35
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 305 307 305 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
Hierarchical clustering was performed using MeV in the TM4 system [25] with complete linkage, Pearson correlation distance and gene centralization. Genes with different expression levels in tumors containing CD44+/CD24- cells and tumors lacking cells with this phenotype were identified using a two-sided t test. To account for multiple comparisons, the false discovery rate was calculated for gene lists. Sixty-nine of the 168 tumors with gene expression profiles were among the 240 tumors for which CD24 and CD44 immunohistochemical stainings were obtained.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
Immunohistochemical expression of CD44 and CD24
###end title 37
###begin p 38
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
We analyzed the presence of CD44 and CD24 antigens on human breast cancer tissues using double-staining immunohistochemistry. The CD44 and CD24 expression was successfully determined in 240 cases after excluding tumors with scarce tissue on the TMA. These 240 tumors did not significantly differ from the excluded 205 tumors in regard to tumor size, lymph node status, S-phase fraction, ER status or disease-free survival. The median age was slightly higher in the included patients (64 years versus 62 years for excluded patients), although not reaching significance.
###end p 38
###begin p 39
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 167 169 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 177 178 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 297 299 297 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 307 309 307 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 631 632 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 901 902 897 898 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Figure 1 displays representative staining patterns of various breast tumors. Tumor cells were distinguishable from stromal cells and inflammatory cells (generally CD44+ and CD24-) by expression of cytokeratin clone AE1/AE3 in adjacent sections. The frequency of tumors with varying degrees of CD44+ and CD24+ tumor cells is presented in Table 1. CD44 showed mainly membranous staining (Permanent Red) with only six tumors displaying cytoplasmic staining, four of which had also membrane staining. Thirty-two percent (77/240) of the tumors had >/= 1% cells with membranous and/or cytoplasmic CD44 expression and were considered CD44+. CD24 was almost exclusively detected in the cytoplasm, with only four tumors displaying membrane DAB staining (all four with positive cytoplasmic staining as well). Forty-six percent (110/240) of the tumors had >/= 1% cells with CD24 staining and were considered CD24+.
###end p 39
###begin p 40
###xml 171 175 171 175 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 205 206 205 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 211 213 211 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 241 243 241 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 313 314 313 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 322 326 322 326 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 365 366 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 371 372 371 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 400 404 400 404 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 435 436 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 441 443 441 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 460 461 460 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 466 468 466 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 506 510 506 510 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 539 540 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 545 547 545 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 39 44 <span type="species:ncbi:9606">human</span>
Immunohistochemical double-staining of human breast tumors for CD44 and CD24. CD44 is stained with Permanent Red and CD24 with diaminobenzidene (DAB). Magnification x 20. (a) A tumor positive for both CD44+/CD24- (white arrow) and CD44-/CD24+ (black arrow) cancer cells, although the predominant phenotype is CD44-/CD24-. (b) Almost all cells in this tumor are CD44+/CD24-. No CD24 staining is seen. (c) A tumor with predominantly CD44+/CD24- cells. A few CD44+/CD24+ cells are also present (black arrow). (d) A tumor positive for the CD44-/CD24+ phenotype. No CD44 staining is present.
###end p 40
###begin p 41
Scoring frequency of different CD44/CD24 phenotypes as determined by immunohistochemistry
###end p 41
###begin p 42
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
Data presented as n (%).
###end p 42
###begin p 43
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 62 64 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 177 178 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 183 185 183 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 413 414 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 419 421 419 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 499 500 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 505 507 505 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 538 539 538 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 576 577 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 582 584 582 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 656 657 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 662 664 662 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 679 684 679 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a, d</xref>
###xml 796 797 796 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 802 803 802 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 969 970 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 975 976 975 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 982 983 982 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 988 990 988 990 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 998 999 998 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1004 1006 1004 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1158 1159 1158 1159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1164 1165 1164 1165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
To determine the proportion of putative tumorigenic CD44+/CD24- cells within each tumor, we scanned for the presence of Permanent Red staining without any DAB interference. CD44+/CD24- tumor cells were detected in 31% (75/240) of the tumors, with the proportion of this phenotype ranging from only a few cells to almost all tumor cells (Figure 1a to 1c). The frequency of tumors with different proportions of CD44+/CD24- tumor cells is presented in Table 1. We also determined the proportion of CD44-/CD24+ and double-positive (CD44+/CD24+) cells in each tumor (Table 1). CD44+/CD24+ cells (Figure 1c) were detected in 6% (15/240) of the tumors, while CD44-/CD24+ cells (Figures 1a, d) were detected in 45% (108/240) of tumors. The majority of tumors included at least a few double-negative (CD44-/CD24-) tumor cells, while a complete lack of both proteins was evident in 35% (83/240). Thirteen percent (30/240) of the tumors were positive for more than one of the CD44+/CD24-, CD44-/CD24+ and CD44+/CD24+ phenotypes, with 5% (11/240) displaying tumor cells of all three phenotypes. In 12% (28/240) of the tumors, the majority (> 50%) of tumor cells was CD44+/CD24-.
###end p 43
###begin title 44
Correlation of CD44/CD24 status with tumor characteristics
###end title 44
###begin p 45
###xml 252 253 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 258 260 258 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 364 366 364 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 407 409 407 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 428 430 428 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 487 489 487 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 520 521 520 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 526 528 526 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 559 560 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 565 567 565 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 832 833 832 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 838 840 838 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1011 1013 1011 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1147 1148 1147 1148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1153 1155 1153 1155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1163 1165 1163 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 190 197 <span type="species:ncbi:9606">patient</span>
###xml 784 789 <span type="species:ncbi:9606">women</span>
HER2 expression was successfully determined in all 240 cases with CD44/CD24 data, and 16% (38/240) were considered strongly positive (score = 3). Information on other clinical variables and patient survival was available from previous studies. The CD44+/CD24- status was significantly correlated to biological characteristics such as low/negative HER2 expression (P = 0.002), elevated expression of CK5/14 (P = 0.012) and EGFR (P = 0.007) (Table 2). Interestingly, all medullary tumors (n = 8) were positive for the CD44+/CD24- phenotype. The presence of CD44+/CD24- tumor cells was not associated with ER and PgR status, with S-phase fraction or with tumor size, nor with lymph node status, menopausal status or age, although showing a tendency of being more common in premenopausal women. Using higher cutoff criteria for the CD44+/CD24- status (10% or 50%) and comparing these 50 tumors or 28 tumors, respectively, with all other tumors gave more or less comparable results, although overall slightly higher P values (data not shown). The only additional significant association was with ER-negative status using a 10% cutoff value for the CD44+/CD24- status (P = 0.041).
###end p 45
###begin p 46
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 25 27 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Association of CD44+/CD24- phenotype with clinical characteristics
###end p 46
###begin p 47
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 26 28 26 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Data presented as n (%). aP values were calculated using Fisher's exact test, except for age where the Mann-Whitney U test was used. The missing categories were always excluded. bScoring as previously described [12]. cScoring as previously described [20].
###end p 47
###begin p 48
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 89 91 89 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 183 184 183 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 189 190 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 192 194 192 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
The presence of CD44-/CD24+ tumor cells was solely associated with strong HER2 staining (P = 0.002) and not with any other tumor characteristics. The presence of double-positive (CD44+/CD24+, n = 15) tumor cells was not associated with any tumor features, although an increase of tumors of medullary type was indicated compared with tumors lacking cells with this phenotype (23% versus 2%).
###end p 48
###begin title 49
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
CD44+/CD24- status and survival
###end title 49
###begin p 50
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 115 117 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 355 357 355 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 369 371 369 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 431 433 431 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 445 447 445 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 695 697 695 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
We did not see any correlation between CD44+/CD24- status and distant disease-free survival, nor between CD44+/CD24- status and site of distant recurrence. Factors significantly correlated to favorable distant disease-free survival at 5-year follow-up (in this cohort of patients receiving adjuvant tamoxifen therapy) included positive ER and PgR status (P = 0.005 and P = 0.037, respectively) and negative CK5/14 and EGFR status (P = 0.035 and P = 0.005, respectively), but not HER2 and lymph node status, while tumor size and a high S-phase fraction reached marginal significance. Lymph node status, however, was correlated to distant disease-free survival in the entire cohort of 445 tumors (P = 0.005).
###end p 50
###begin title 51
Definition of breast cancer subgroups by tumor markers and correlation with gene expression subtypes
###end title 51
###begin p 52
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 420 422 420 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 440 442 440 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 459 461 459 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 499 501 499 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 622 624 622 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 696 698 696 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
The CD44+/CD24- phenotype was clearly related to certain tumor biological characteristics. To study this relation in more depth, we used five protein markers available for 232 out of the 240 cases with CD44/CD24 data to define five tumor subgroups. Tumors positive for ER and/or PgR were designated steroid receptor positive (SR+). The SR and HER2 status was used to broadly divide tumors into four subgroups; SR+HER2- (n = 150), SR+HER2+ (n = 14), SR-HER2+ (n = 24), and SR-HER2- (triple negative, n = 44). The latter group was further subdivided into a subgroup expressing basal CK5/14 and/or EGFR (SR-HER2- basal-like, n = 30), and a subgroup negative for all five markers (SR-HER2- nonbasal, n = 14).
###end p 52
###begin p 53
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Gene expression data were available for 69 of the 232 tumors, which allowed us to correlate our five subgroups, as defined by the five tumor markers, with breast cancer subtypes defined by gene expression profiling and intrinsic gene lists [9,10]. As seen in Figure 2, SR+HER2- tumors were clearly enriched for luminal A tumors, while SR-HER2- basal-like tumors corresponded prominently to the basal-like subtype defined by gene expression profiling. As expected, SR-HER2+ tumors correlated well with the HER2+ subtype. The SR-HER2- nonbasal subgroup showed no clear association with any tumor subtype - and only two tumors were SR+HER2+, making it difficult to draw any conclusions for this subgroup. We therefore conclude that tumor classification based on a combination of five commonly used tumor protein markers is biologically relevant for subgroup analysis in our tumor material.
###end p 53
###begin p 54
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 379 380 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 385 387 385 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 395 396 395 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 401 403 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Hierarchical clustering of 69 tumor samples with available gene expression data. Clustering was based on 364 genes from the intrinsic gene list published by Sorlie and colleagues [9] that matched our cDNA clones. Colored boxes indicate classification of each tumor into subtypes/subgroups. Filled or open boxes indicate the percentage of cells in each tumor positive for the CD44+/CD24- and CD44-/CD24+ phenotypes as determined by immunohistochemistry. SR, steroid receptor. Hu classification, Hu and colleagues [10].
###end p 54
###begin title 55
CD44/CD24 status in different breast cancer subgroups
###end title 55
###begin p 56
###xml 78 80 78 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 92 94 92 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The expression of CD44 and CD24 differed significantly between the subgroups (P = 0.001 and P = 0.035, respectively) (Table 3). CD44 was highly expressed in the SR-HER2- basal-like subgroup, with 63% of the tumors being positive compared with 32% for the entire cohort, and was very lowly expressed in the HER2+ groups, with only 14% and 17% of the tumors being positive in the SR+HER2+ and SR-HER2+ groups, respectively. CD24 was highly expressed in the SR-HER2+ group (75% compared with 47% for the entire cohort).
###end p 56
###begin p 57
Association of CD44/CD24 phenotypes with breast cancer subgroups.
###end p 57
###begin p 58
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 48 50 48 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Data presented as n (%). SR, steroid receptor. aP values were calculated using Fisher's exact test.
###end p 58
###begin p 59
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 51 53 51 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 117 119 117 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 256 258 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 467 468 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 473 475 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 501 503 501 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 515 517 515 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 562 563 562 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 568 570 568 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 679 680 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
The frequency of tumors positive for the CD44+/CD24- phenotype varied significantly between the different subgroups (P < 0.001, Table 3). While close to two-thirds (63%) of tumors resembling the basal-like subtype (SR-HER2- basal-like) expressed CD44+/CD24- cells, this phenotype was very low in HER2+ tumors, regardless of SR status: 8% in SR-HER2+ tumors and 14% in SR+HER2+ tumors (Table 3). The divergence between subgroups remained when the cutoff level for CD44+/CD24- was raised to 10% or 50% (P = 0.003 and P = 0.033, respectively). The frequency of CD44+/CD24- cells within tumors positive for this phenotype was also higher in basal-like tumors, as indicated in Figure 2 for the 69 tumors with gene expression data.
###end p 59
###begin p 60
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 95 97 95 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The proportion of tumors with CD44-/CD24+ cells also differed significantly between subgroups (P = 0.027), with the highest proportion in the two HER2+ groups (SR-HER2+ and SR+HER2+) (Table 3). The presence of double-positive (CD44+/CD24+) and double-negative (CD44-/CD24-) tumor cells did not differ between subgroups (Table 3).
###end p 60
###begin title 61
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
CD44+/CD24- status in BRCA1-defective tumors
###end title 61
###begin p 62
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 58 60 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
Since there was a clear correlation between the CD44+/CD24- status and the basal-like tumor subtype, we extended the immunohistochemical analysis to an additional TMA including tumors from BRCA1 hereditary breast cancer patients, known to be of predominantly basal-like phenotype [9]. A basal-like status was verified for nine of our BRCA1 hereditary tumors for which gene expression data were available.
###end p 62
###begin p 63
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 163 165 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 331 332 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 337 339 337 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 392 398 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 494 495 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 500 502 500 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Seventeen of the 23 BRCA1-defective tumors were successfully stained for CD44 and CD24 expression. The frequency of tumors with different proportions of CD44+/CD24- cells is presented in Table 4. Ninety-four percent (16/17) of the tumors were positive for this phenotype, thus corroborating the finding of a high proportion of CD44+/CD24- cells in the SR-HER2- basal-like subgroup (Table 4). BRCA1 germline mutant tumors, however, also had a high proportion (70%) of cells positive for the CD44-/CD24+ phenotype, considerably higher than the 40% seen among SR-HER2- basal-like tumors.
###end p 63
###begin p 64
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 31 33 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Scoring frequency of CD44+/CD24- cells in BRCA1-defective breast tumors in comparison with SR-HER2- basal-like tumors
###end p 64
###begin p 65
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
Data presented as n (%). SR, steroid receptor.
###end p 65
###begin title 66
Correlation to published prognostic gene signatures
###end title 66
###begin p 67
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 117 119 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 126 128 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 338 340 338 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 398 399 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 404 406 404 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 437 439 437 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 450 452 450 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 621 623 621 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 632 634 632 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 646 648 646 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
We correlated the presence of CD44+/CD24- cells to two gene signatures with prognostic value specific for either CD44+ or CD24+ breast cancer cells published by Shipitsin and colleagues [5]. Signatures A and B are associated with shorter and longer distant recurrence-free survival time, respectively. A positive correlation of CD44+/CD24- cells to signature A was seen if the cutoff level for CD44+/CD24- was 50% or 75% positive cells (P = 0.05 and P = 0.008, respectively) but not when using lower cutoff levels. A negative correlation to signature B was seen when using cutoff levels of 0%, 10% or 75% positive cells (P < 0.001, P < 0.001 and P = 0.01, respectively).
###end p 67
###begin title 68
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 43 45 43 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Gene expression signature of the CD44+/CD24- phenotype
###end title 68
###begin p 69
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 58 60 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 201 203 201 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
To identify a gene expression signature for the CD44+/CD24- phenotype, we used the 69 tumors with gene expression data and looked for genes differentially expressed between tumors containing CD44+/CD24- cells and tumors lacking such cells. The top 20 genes are displayed in Table 5. Interestingly, CD44 emerged as the second ranked gene, demonstrating a good correspondence between protein and mRNA levels for this gene - although the top 20 genes collectively had a relatively high false discovery rate of 28%.
###end p 69
###begin p 70
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Top 20 genes differing between tumor with and without the presence of CD44+/CD24- tumor cells
###end p 70
###begin p 71
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 300 302 300 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
aIntegrated Molecular Analysis of Genomes and their Expression (IMAGE) consortium cDNA clone number. bClones mapped using UniGene Build 208 (National Center for Biotechnology Information, Bethesda, Maryland, USA). cGenes are either upregulated (+) or downregulated (-) in tumors containing CD44+/CD24- tumor cells.
###end p 71
###begin title 72
Discussion
###end title 72
###begin p 73
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 312 314 312 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
The concept of cancer stem cells relies on the presence of a subpopulation of cells within tumors that drives tumorigenesis, as well as giving rise to a large population of differentiated progeny that constitute the bulk of the tumor but lack tumorigenic potential [26]. Multiple studies indicate that CD44+/CD24- breast cancer cells have tumor-initiating properties [1-3].
###end p 73
###begin p 74
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
In the present study, we have explored the dual expression of CD44 and CD24 in a sample of 240 stage II breast tumors with specific regard to breast cancer subtypes. The CD44 staining was almost exclusively membranous, which is concordant with prior literature [27], while CD24 predominantly stained the cytoplasm. Earlier publications have shown either membranous and/or cytoplasmic CD24 staining [28,29]. Bircan and colleagues observed a cytoplasmic CD24 staining pattern in neoplastic breast tissue while it was mainly detected in the cell membrane in normal breast [30]. Intracytoplasmic CD24 expression has been suggested to reflect overexpression of the protein or disturbance of the protein distribution or degradation in neoplastic cells [31]. It is reasonable to suspect that cells with a cytoplasmic CD24 pattern also express CD24 protein on the cell surface. The specificity of the CD24 antibody has earlier been ascertained by flow cytometric analysis [32].
###end p 74
###begin p 75
###xml 363 365 363 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 373 375 373 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 444 446 444 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 454 456 454 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 554 555 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 579 581 579 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 622 624 622 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 685 687 685 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 719 721 719 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 856 858 856 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 865 867 865 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Overall, we saw a large heterogeneity of CD44 and CD24 expression between tumors, but also within tumors where the proportion of positive cells varied considerably. Interestingly, tumor cells were mostly positive for either CD44 or CD24 and rather few tumors contained double-positive cells, although it was quite common that individual tumors contained both CD44+ and CD24+ cells. A recent study by Shipitsin and coworkers implicated that CD24+ and CD44+ cells within breast carcinomas represent defined cell populations with distinct genetic profiles [5]. They showed that CD24+ cells were more differentiated while CD44+ cells had more progenitor-like features, suggesting that CD24+ cells might be derived from CD44+ cells. Findings from our study could support this hypothesis, in that the variable presence of tumor cells that are largely either CD44+ or CD24+ may reflect the current state of a tumor undergoing constant cell renewal, differentiation and death at a pace defined by their intrinsic machinery and interaction with surrounding stroma.
###end p 75
###begin p 76
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 75 77 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 407 408 407 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 413 415 413 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 520 521 520 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 526 528 526 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
###xml 544 549 <span type="species:ncbi:9606">human</span>
Contradictive to results by Al-Hajj and colleagues demonstrating CD44+/CD24- cells in all their breast cancer samples [1], we only detected cells with this phenotype in 31% of our tumors. This discordance could depend on their study involving mainly metastatic tissues, including only one primary tumor. Metastatic tumor cells may have a more stem cell-like phenotype, as indicated by enrichment of the CD44+/CD24- phenotype in bone marrow micrometastasis of breast cancer patients [33]. A recent study demonstrated CD44+/CD24- cells in 59% of human breast tumors, further supporting that not all breast tumors contain cells with this phenotype [34].
###end p 76
###begin p 77
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 28 30 28 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 313 315 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
We found that the CD44+/CD24- status was associated with low/negative HER2 expression and with elevated expression of CK5/14 and EGFR, as well as with medullary histological type, all known characteristics of the basal-like subtype of breast cancer. This motivated further analysis of the prevalence of CD44+/CD24- cells in different tumor subtypes.
###end p 77
###begin p 78
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 570 571 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 576 578 576 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 662 663 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 668 670 668 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 907 908 907 908 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 913 915 913 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 927 928 927 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Since previous studies have demonstrated a good resemblance of subgroups defined by common tumor markers to molecular subtypes defined by mRNA expression patterns [13,14], we used cytosolic protein levels of ER and PgR and used TMA immunostaining of HER2, CK5/14 and EGFR to classify the material into five tumor subgroups. Using available gene expression data for 69 of the tumors and using published intrinsic gene lists [9,10], we could demonstrate a reasonable correlation to molecular subtypes for three of our five subgroups, justifying a subgroup analysis of CD44+/CD24- expression. We could thereby demonstrate an association between the presence of CD44+/CD24- tumor cells and a basal-like subgroup of breast cancer. This finding is consistent with a recent publication where Sheridan and colleagues observed a correlation between breast cancer cell lines with a basal/myoepithelial origin and CD44+/CD24- expression [3].
###end p 78
###begin p 79
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 88 90 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 153 155 153 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 533 539 533 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 820 821 820 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 826 828 826 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 884 886 884 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Moreover, we observed that basal-like tumors often had a higher proportion of CD44+/CD24- cells, while tumors of other subtypes that contained CD44+/CD24- cells generally had a lower number of cells with this phenotype. This observation corroborates prior work indicating that basal-like tumors have a greater stem cell-like phenotype [35]. These tumors may originate from the most primitive ER-negative stem/progenitor cells, suggesting a block in differentiation upstream of ER-positive progenitor cells [36]. Tumors developing in BRCA1 germline mutation carriers are typically of basal-like subtype, possibly due to the critical role BRCA1 plays in the differentiation of ER-negative stem/progenitor cells to ER-positive luminal cells [37]. Accordingly, we found that all but one of the 17 BRCA1 tumors contained CD44+/CD24- cells, further illustrating the correlation between CD44+ status and basal-like/BRCA1-like tumors.
###end p 79
###begin p 80
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 155 157 155 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 206 207 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 212 214 212 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 609 611 609 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 705 707 705 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
Interestingly, the HER2+ tumor subtype, generally considered an aggressive form of breast cancer, displayed a low frequency of tumors containing CD44+/CD24- cells and was in fact often positive for the CD44-/CD24+ phenotype. CD24 expression has been shown to contribute to the more differentiated state of committed cells [38], but has also been associated with rapid cell spreading, increased cell motility and invasion [39]. In normal breast epithelium, basal/myoepithelial cells but not luminal epithelial cells express CD44 [27] while CD24 is highly expressed in luminal cells [40]. The predominantly CD24+ phenotype of HER2+ tumors may reflect the origin for at least some of these tumors from a CD24+ luminal epithelial cell type [40].
###end p 80
###begin p 81
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 53 55 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 349 350 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 355 357 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
We did not see any association between the CD44+/CD24- status and markers known to be important for the clinical outcome, including tumor size, nodal status or S-phase fraction. These results are partly in accordance with previous observations by Abraham and colleagues [6], although these authors reported that tumors with a higher fraction of CD44+/CD24- cells were more commonly found in patients diagnosed with distant metastases. We saw no such trend in our material, regardless of whether analyzing the whole material or different subgroups separately.
###end p 81
###begin p 82
###xml 220 222 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 249 251 249 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 570 572 570 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 661 662 661 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 667 669 667 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 749 750 749 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 755 757 755 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
Since all patients in our study received adjuvant tamoxifen therapy the lack of correlation to survival should however be cautiously interpreted. We therefore evaluated prognostic gene signatures specific for either CD44+ cells (signature A) or CD24+ cells (signature B) published by Shipitsin and colleagues [5], shown to be associated with short and long distant recurrence-free survival, respectively, in patients not undergoing adjuvant systemic therapy. Interestingly, we saw a significant positive correlation of tumors with a high (> 50%) proportion of CD44+/CD24- cells to signature A, and a significant negative correlation between the presence of CD44+/CD24- cells and signature B. This observation indicates that a high proportion of CD44+/CD24- cells could therefore be a marker of aggressive phenotype also in our material, although we saw no correlation with prognosis.
###end p 82
###begin p 83
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 225 226 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 388 390 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 486 488 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
We detected a gene expression signal for tumors containing CD44+/CD24- cells. Although the false discovery rate was high, the signature is strengthened by the fact that CD44 occurs as the top second gene. Interestingly, alpha6-integrin also appears as one of the top overexpressed genes. This gene (also known as CD49f) has previously been used to identify mammary epithelial stem cells [41] and was recently demonstrated to be necessary for tumorigenicity of MCF7 breast cancer cells [42].
###end p 83
###begin title 84
Conclusion
###end title 84
###begin p 85
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 73 75 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 557 558 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 563 565 563 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Our results demonstrate a clear variation in the prevalence of CD44+/CD24- tumor cells between breast tumors of different subtypes. The occurrence of this phenotype is high in basal-like tumors - and especially in BRCA1 hereditary tumors - is lower in tumors of luminal type and is particularly low in the HER2+ tumors, irrespective of ER status. These results emphasize the biological heterogeneity of breast cancer and an enrichment of putative tumor-initiating cells in the aggressive basal-like tumor subtype. Far from all basal-like tumors contain CD44+/CD24- cells, however, and their scarcity in HER2+ tumors suggests that tumorigenicity may not be confined to cells of this phenotype and that other markers remain to be identified. Moreover, the obvious heterogeneity of cells with various CD44/CD24 expression within individual tumors may be indicative of a cancer stem cell subpopulation giving rise to more differentiated and committed cell populations. This does by no means exclude the coexistence of cancer cell clones of independent origin, evolution and tumorigenic ability.
###end p 85
###begin title 86
Abbreviations
###end title 86
###begin p 87
CK = cytokeratin; DAB = diaminobenzidene; EGFR = epidermal growth factor receptor; ER = estrogen receptor; PgR = progesterone receptor; SR = steroid receptor; TMA = tissue microarray.
###end p 87
###begin title 88
Competing interests
###end title 88
###begin p 89
The authors declare that they have no competing interests.
###end p 89
###begin title 90
Authors' contributions
###end title 90
###begin p 91
GH participated in the design of the study, evaluated the immunostainings, performed the statistical analysis and drafted the manuscript. P-OB supported the statistical analysis. MR conducted the gene expression classification and supported the draft of the paper. LHS and SKG-S provided gene expression data and comments to the manuscript. KL conducted the immunostainings. DG supported the evaluation of the immunostainings. MF contributed to the design of the study and the interpretation of the results. AB participated in the design and coordination of the study and helped to draft the manuscript. CH conceived of the study, participated in its design, performed the microarray analysis and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
The authors thank the South Sweden Breast Cancer Group for providing access to breast cancer samples. The present study was supported by grants from the Mrs Berta Kamprad Foundation, the Gunnar Nilsson Cancer Foundation, the Royal Physiographical Society in Lund, the Crafoord Foundation, Research Founds from Lund University Hospital, the Swedish Cancer Society, the Swedish Research Council, the King Gustav V's Jubilee Foundation, the Ingabritt and Arne Lundberg Foundation, the Swedish Foundation for Strategic Research, the Knut and Alice Wallenberg Foundation via the SCIBLU program at Lund University, the US Department of Defense Era of Hope Award and the US National Institutes of Health Medical Scientist Training Grant 5T32 GM07367-29.
###end p 93
###begin article-title 94
Prospective identification of tumorigenic breast cancer cells
###end article-title 94
###begin article-title 95
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties
###end article-title 95
###begin article-title 96
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis
###end article-title 96
###begin article-title 97
###xml 20 27 20 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">(-/low)</sup>
###xml 32 34 32 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation
###end article-title 97
###begin article-title 98
Molecular definition of breast tumor heterogeneity
###end article-title 98
###begin article-title 99
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 24 30 24 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis
###end article-title 99
###begin article-title 100
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 100
###begin article-title 101
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
###end article-title 101
###begin article-title 102
Repeated observation of breast tumor subtypes in independent gene expression data sets
###end article-title 102
###begin article-title 103
The molecular portraits of breast tumors are conserved across microarray platforms
###end article-title 103
###begin article-title 104
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome
###end article-title 104
###begin article-title 105
###xml 44 51 <span type="species:ncbi:9606">patient</span>
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
###end article-title 105
###begin article-title 106
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes
###end article-title 106
###begin article-title 107
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
###end article-title 107
###begin article-title 108
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair
###end article-title 108
###begin article-title 109
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up
###end article-title 109
###begin article-title 110
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group
###end article-title 110
###begin article-title 111
Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates
###end article-title 111
###begin article-title 112
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group
###end article-title 112
###begin article-title 113
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer
###end article-title 113
###begin article-title 114
Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer - clinical associations and reasons for discrepancies
###end article-title 114
###begin article-title 115
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma
###end article-title 115
###begin article-title 116
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
###end article-title 116
###begin article-title 117
BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data
###end article-title 117
###begin article-title 118
TM4: a free, open-source system for microarray data management and analysis
###end article-title 118
###begin article-title 119
Cancer stem cells in solid tumors
###end article-title 119
###begin article-title 120
Gains and losses of CD44 expression during breast carcinogenesis and tumour progression
###end article-title 120
###begin article-title 121
###xml 21 26 <span type="species:ncbi:9606">human</span>
CD24 is a marker for human breast carcinoma
###end article-title 121
###begin article-title 122
Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers
###end article-title 122
###begin article-title 123
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study
###end article-title 123
###begin article-title 124
###xml 82 89 <span type="species:ncbi:9606">patient</span>
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival
###end article-title 124
###begin article-title 125
CD24 expression is a new prognostic marker in breast cancer
###end article-title 125
###begin article-title 126
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype
###end article-title 126
###begin article-title 127
###xml 57 60 57 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">(+)</sup>
###xml 65 73 65 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">(-/low) </sup>
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">(-)</sup>
###xml 89 93 89 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">(+) </sup>
The clinicopathologic and prognostic significance of CD44(+)/CD24(-/low) and CD44(-)/CD24(+) tumor cells in invasive breast carcinomas
###end article-title 127
###begin article-title 128
Deconstructing the molecular portrait of basal-like breast cancer
###end article-title 128
###begin article-title 129
Breast cancer, stem/progenitor cells and the estrogen receptor
###end article-title 129
###begin article-title 130
###xml 16 21 <span type="species:ncbi:9606">human</span>
BRCA1 regulates human mammary stem/progenitor cell fate
###end article-title 130
###begin article-title 131
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse CD24 is required for homeostatic cell renewal
###end article-title 131
###begin article-title 132
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis
###end article-title 132
###begin article-title 133
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells
###end article-title 133
###begin article-title 134
Purification and unique properties of mammary epithelial stem cells
###end article-title 134
###begin article-title 135
Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line
###end article-title 135

